(Received 14 April 1997; accepted 13 June 1997)
Published Online: 1998
| ||Format||Pages||Price|| |
|PDF (300K)||6||$25||  ADD TO CART|
Cite this document
This study was designed to compare results obtained from two separate on-site drug testing kits (ONTRAK TESTCUP and Abuscreen ONTRAK) with those obtained from laboratory based immunoassay and GC/MS. Abuscreen ONLINE immunoassay was used to select 250 negative samples and 100 presumptive-positive samples each for cocaine/metabolites, opiates and cannabinoids. Presumptive-positive samples were selected if the immunoassay response was ⩾300 ng/mL for cocaine/metabolites (BZE), ⩾300 ng/mL for opiates or ⩾50 ng/mL for cannabinoids (THC-COOH). GC/MS was used to confirm that each selected sample contained ⩾150 ng/mL BZE, ⩾300 ng/mL morphine/codeine or ⩾15 ng/mL THC-COOH.
TESTCUP results had a 100% agreement with GC/MS and a >99% agreement with ONLINE when testing negative samples. The agreement between TESTCUP and ONLINE results for samples containing opiates was 100%. Results of testing samples containing BZE with TESTCUP demonstrated a 98% agreement with both GC/MS and ONLINE. Both discrepant samples contained BZE at concentrations ⩽300 ng/mL. The least agreement between TESTCUP and ONLINE results was found when testing samples containing THC-COOH. The agreement with ONLINE and GC/MS was 92% and all discrepant samples had GC/MS determined THC-COOH concentrations less than 50 ng/mL. A 100% agreement was obtained between expected and recorded TESTCUP results for QC samples fortified to contained BZE, morphine or THC-COOH at concentrations within 120% of the screening cutoffs.
ONTRAK had a 100% agreement with both GC/MS and ONLINE when testing negative samples and samples that contained opiates. ONTRAK had a 91% agreement with GC/MS and ONLINE for testing of samples that contained BZE. The least agreement between ONTRAK and ONLINE results was found when testing samples that contained THC-COOH. The agreement was 89%, however, all discrepant samples contained GC/MS concentrations of THC-COOH less that the 50 ng/mL cutoff. With ONTRAK, a 100% agreement was obtained between expected and recorded results on QC samples that contained morphine or THC-COOH and a 97.7% agreement was obtained between expected and recorded results on QC samples that contained BZE.
Assistant Director, Center for Human Toxicology and Research assistant professor, Pharmacology and Toxicology Center for Human Toxicology University of Utah, Salt Lake City, Utah
Laboratory Director, Workplace Drug Testing Division, Northwest Toxicology, Inc., Salt Lake City, Utah
Operations Manager, Workplace Drug Testing Division, Northwest Toxicology, Inc., Salt Lake City, Utah
Assistant Director, Center for Human Toxicology, University of Utah, Salt Lake City, Utah
Laboratory Technician, Center for Human Toxicology, University of Utah, Salt Lake City, Utah
Stock #: JFS16086J